We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ENERZAIR BREEZHALER (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
ENERZAIR BREEZHALER
Date registered
Evaluation commenced
Decision date
Approval time
226 working days (255)
Active ingredients
glycopyrronium bromide; indacaterol acetate; mometasone furoate
Registration type
EOI
Indication
New Combination
ENERZAIR BREEZHALER (hard capsule) is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.